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In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog 
JCC76 in aromatase inhibitors-insensitive breast cancer cells 
Bo Zhong , Xiaohan Cai , Xin Yi , Aimin Zhou , Shiuan Chen , Bin Su 
Introduction 
Breast Cancer is the most common cancer in women in the 
United States and ranks second only to lung cancer as a cause of 
cancer-related deaths. Among all breast cancer patients, about 65% 
have hormone-dependent carcinoma, which requires estrogen for 
tumor growth. Aromatase is one of the key enzymes responsible 
for the biosynthesis of estrogen. Aromatase inhibitors (Ats). which 
induce estrogen deprivation in postmenopausal women, have been 
proving to be more effective than tamoxifen for the treatment of 
hormone dependent breast cancer [1-3]. 
The 'third generation Ais' are potent and highly selective. As 
a consequence, they efficiently block the conversion of andro-
gens ( testosterone and androstenedione) to estrogens ( estradiol 
and estrone, respectively) in peripheral tissues and breast tumors. 
Of the three Ais currently approved by the FDA for breast 
cancer treatment, letrozole and anastrozole are nonsteroidal tri-
azole compounds, whereas exemestane is a steroidal analog of 
androstenedione. In recent years. Ais have been used as first-line 
hormonal therapy for patients with advanced estrogen dependent 
breast cancer [ 1 ]. However, long term estrogen deprivation caused 
by Ais can lead to significant endocrine therapy resistance, which 
has been demonstrated in preclinical models by several laborato-
ries [4-8]. As a consequence. efforts are being made to search new 
agents that are able to overcome AI resistance [9-11 ]. 
A growing body of experimental and epidemiological evidence 
suggests that the use of NSAIDs (Non-steroidal anti-inflammatory 
drugs) may decrease the incidence of mammary cancer, tumor bur-
den, and tumor volume [ 12-16]. Celecoxib, a cyclooxygenase-2 
(COX-2) selective inhibitor, has strong chemo-preventive activ-
ity against mammary carcinoma in rats in some studies [17]. In 
addition to COX inhibition, these small molecules also block other 
cellular pathways to affect cellular function. For example, celecoxib 
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can block the phosphoinositide 3-kinase (PI3K)/phosphoinositide-
dependent kinase (PDK)/AKT pathway to induce apoptosis in
prostate cancer cells [18–20]. The COX-2 inhibitor nimesulide
was found to suppress the development of 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland
carcinogenesis in rats [21,22]. Derivatives of nimesulide have been
synthesized, and their pharmacological effect on breast cancer
cells has been primarily studied [23,24]. These new compounds
suppress aromatase in SK-BR-3 breast cancer cells through a
non-direct inhibitory mechanism [23,25]. They also selectively
induce apoptosis in Her2 over expressed breast cancer cells [26].
It has been well documented that growth factor pathways which
include Her2 and IGFR are up regulated in AI resistant breast
cancer cells [8,27,28]. We hypothesize that nimesulide analogs
might potentially be able to overcome AI resistance, since they
selectively inhibit Her2 over-expressing breast cancer cell growth
[26].
In the present study, we examined JCC76
{Cyclohexanecarboxylic acid [3-(2,5-dimethyl-benzyloxy)-4-
(methanesulfonyl-methyl-amino)-phenyl]-amide} (Fig. 1), an
analog of COX-2 inhibitor nimesulide, in an AI resistance breast
cancer model in vitro and in vivo. LTEDaro cell line, which was
developed from MCF-7aro (MCF-7 cells stably transfected with
Fig. 1. Structure of nimesulide and JCC76.
aromatase full gene) cells by hormone deprivation over a year
and was used as the AI resistance model [29]. Compound JCC76
inhibited LTEDaro cell growth via induction of cell apoptosis
through the decreasing of pAKT, pBAD and BCL-2 protein levels.
It also induced cell apoptosis and inhibited tumor growth in the
xenograft formed by using LTEDaro cells in ovariectomized nude
mice. The synthesis of JCC76 derivatives has been well established
[24,30]. The information gained from this study further elucidates
the biological mechanisms through which compound JCC76 over-
Fig. 2. Characterization of LTEDaro cells. MCF-7aro and LTEDaro cells were exposed to T or E2 and various AIs for 7days. Cell viabilitywasmeasured byMTT assay as described
in Section 2. The results were normalized against a control treatment with vehicle. Each data bar represents themean results of six independent determinations± SE. Similar
results were obtained in at least three independent experiments. (A) AIs decreased MCF-7aro cell proliferation stimulated by testosterone. *P<0.005 vs. DMSO by unpaired
t test, **p<0.005 vs. T treatment by unpaired t test. (B) LTEDaro cells did not respond to hormone and AIs in the proliferation assay. (C) MCF-7aro and LTEDaro cells were
harvested as described in Section 2. Levels of IGFR, Her2, pAKt, AKT, pERK, ERK, pBAD, BAD, BCL-2, BCL-XL proteins were analyzed by Western blotting of cell extracts with
speciﬁc antibodies.
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Fig. 3. Inhibition of LTEDaro cell growth by JCC76. Cells were treated with compound as indicated for 72h. Cell viability after drug treatment was determined by the MTT
assay. Each data point represents themean results of six independent determinations± SE. Similar results were obtained in at least three independent experiments. (A) JCC76
dose-dependently suppressed LTEDaro cell proliferation. (B) JCC76 time-dependently inhibited LTEDaro cell growth. (C) JCC76 selectively inhibited Her2 overexpressing
breast cancer cell growth.
comes AI resistance, which makes the compound a promising lead
for the further drug discovery.
Materials and methods
Reagents
Trypsin and all enzymes were obtained from Invitrogen
(Carlsbad, CA). Testosterone and 17-estradiol were from Sigma
Chemical (St. Louis, MO). All antibodies were from Cell Signaling
(Danvers, MA) or Santa Cruz Biotechnology (Santa Cruz, CA).
Synthesis of JCC76
Compound JCC76 was synthesized according to the published
procedure [24,30], and its structure and purity was conﬁrmed by
NMR and HPLC (Beckman HPLC, C18 column from Phenomenex,
10mM ammonia acetate in 90% methanol as mobile phase, ﬂow
rate as 0.2mL/min, UV detector setting up at 290 and 296nM).
Compound JCC76 used in the study has a purity of 98.6%.
Cell culture
The ER-positive aromatase-overexpressing MCF-7aro was pre-
pared by stable transfection with the human placental aromatase
gene and neomycin selection, as described previously [31]. The
cells were cultured in MEM, supplemented with 10% fetal bovine
serum (FBS), 2mmol/L l-Glutamine, 1mmol/L sodium pyruvate,
100U/mL penicillin–streptomycin and 200mg/L G418 (Invitrogen,
Carlsbad, CA). SKBR-3, MDA-MB-231, HCC38 and BT20 cells were
obtained from ATCC (Rockville, MD). These cell lines were cul-
tured in MEM, supplemented with 10% fetal bovine serum (FBS),
2mmol/L l-Glutamine, 1mmol/L sodium pyruvate, and 100U/mL
penicillin–streptomycin. LTEDaro cells, which were developed by
hormone deprivation of MCF-7aro cells for more than one year,
were cultured in the same media, with charcoal stripped fetal
bovine serum(CSFBS). Cell culturesweregrownat37 ◦C inahumid-
iﬁed atmosphere of 5% CO2 in a Hereaus CO2 incubator.
Western blot
Cells were cultured in 60-mm culture dishes, incubated with
DMSO or JCC76 for 24h, and then lysed with CelLytic M
(Sigma–Aldrich) supplemented with protease inhibitor tablets
(Roche, Indianapolis, IN). Cell lysates were sonicated brieﬂy to
reduce viscosity. Sixty micrograms of protein for each sample
were boiled with 1× loading buffer (100mmol/L DTT plus bro-
mophenol blue) for 5min. Samples were then electrophoresed
on a 10% SDS-polyacrylamide gel and transferred to a Trans-Blot
nitrocellulose membrane (Bio-Rad) using a Trans-Blot SD semidry
transfer cell (Bio-Rad) at 100mA for 90min. The membrane was
blocked for 2h with 5% nonfat milk in 1x TBS-T at room tem-
perature to reduce background and then incubated with primary
antibody in 1% bovine serum albumin at 4 ◦C overnight. After
the membrane was incubated with the primary antibody and
washed four times with 1x TBS-T for 5min each wash, it was
incubated with the secondary antibody in 5% nonfat milk for
60min at room temperature. The membrane was washed four
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Fig. 4. JCC76 induced LTEDaro cell apoptosis. (A) JCC76 treatment led to LTEDaro cell shrinking, rounding, and detaching from the dish. In addition, staining cells with
the DNA-binding ﬂuorescent chromatin dye Hoechst 33342 revealed irregularly punctate nuclei, characteristic of cells undergoing programmed cell death. (B) Cell Death
Detection ELISA assay exhibited cytoplasmic histone-associated DNA fragments after the treatment. Columns, mean of three independent experiments; bars, ±SE. *P<0.005
vs. DMSO by unpaired t test (C) Annexin V analysis of phosphatidylserine externalization revealed that JCC76 at 5 and 10mol/L induced 54% and 78% apoptotic death in
LTEDaro cells after 48h treatment, respectively. Cells were treated as indicated for 48h and assessed for phosphatidylserine externalization by ﬂow cytometry after staining
with ﬂuorescence-labeled Annexin V and propidium iodide. Representative quadrantal plots of data from dual-color ﬂow cytometry of treated LTEDaro cells. (D) Apoptosis
was also characterized by western blot analysis of PARP cleavage to the apoptosis-speciﬁc 85-kDa fragment examined by immunoblotting as described in Section 2.
times again for 5min each time with 1x TBS-T and incubated
with SuperSignal West Pico Chemiluminescent Substrate (Pierce),
according to the protocol of the manufacturer. The membrane blot
was exposed to Basic Autorad Film (ISC Bioexpress, Kaysville, UT)
and developed using a Konica SRX-101A (Konica, Tokyo, Japan).
The blot was reprobed with anti-actin (Santa Cruz Biotechnology)
at 1:2000 dilution as a loading control. Anti-pAKt, AKt, p-ERK,
ERK, Her2, pBAD112, pBAD136, BAD, BCL-2, BCL-X were diluted
(1:1000).
Cell proliferation
The effect of compound JCC76 on breast cancer cell proliferation
was assessed by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide assay (MTT) in six replicates.
Cells were grown in culture medium in 96-well, ﬂat-bottomed
plates for 24h, and exposed to various concentrations of com-
pound I dissolved in DMSO (ﬁnal concentration ≤0.1%) in medium
for different time intervals. For androgen and estrogen stimulated
cell growth, cells were hormone starved for three days before
the assay, and the cells were allowed to growth for 7 days in
the assay. Controls received DMSO vehicle at a concentration
equal to that in drug-treated cells. The medium was removed,
replaced by 200L of 0.5mg/mL of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide in fresh medium, and
cells were incubated in the CO2 incubator at 37 ◦C for 2h.
Supernatants were removed from the wells, and the reduced 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
dye was solubilized in 200L/well DMSO. Absorbance at 570nm
was determined on a plate reader.
013
Fig. 5. Analysis of the pathways involved in JCC76-induced apoptosis. LTEDaro cells
were treated with JCC76 with various concentrations for 48h. Levels of pAKT, AKT,
pERK, ERK, pBAD, BAD, BCL-2, BCL-XL and cytochrome c proteins were analyzed by
Western blotting of cell extracts with speciﬁc antibodies as described in Section 2.
Morphological examination of apoptotic changes
Cells were treated with the indicated compound at various
concentrations and times, and then stained with Hoechst 33342
(5g/mL) at 37 ◦C for 30min. The stained cells were examined
by ﬂuorescence microscopy using a microscope (Nikon, Tokyo)
equipped with an epi-illuminator and appropriate ﬁlters.
Apoptosis detection by enzyme-linked immunosorbent assay
(ELISA)
Drug-induced apoptotic cell death was assessed using the Cell
Death Detection ELISA kit (Roche Diagnostics), which quantitates
cytoplasmic histone-associated DNA fragments in the form of
mononucleosomes or oligonucleosomes. Cells were seeded and
incubated at 10,000 cells per well in 12-well ﬂat-bottomed plates
in 10% CDFBS-supplemented MEM medium. After 24h, cells were
treated with JCC76 for 48h at the indicated concentrations. Both
ﬂoating and adherent cells were collected and the assay was done
according to the manufacturer’s instructions.
Flow cytometry analysis
For all of the assays, cells were treated for 48h. To analyze
cell cycle proﬁle, treated LTEDaro cells were ﬁxed overnight with
70% EtOH at −20 ◦C and stained with propidium iodide buffer
[38mM sodium citrate (pH 7.5), 69M propidium iodide and
120g/mL RNase A]. For assessment of apoptosis, treated cells
were labeledwith 5LAnnexinV-FITC (Invitrogen) and0.1g pro-
pidiumiodide (Sigma–Aldrich) in100Lbindingbuffer [10mmol/L
HEPES, 140mmol/L NaCl and 2.5mmol/L CaCl2 (pH 7.4)] contain-
ing 5×105 cells. Samplesweremixed gently and incubated at room
temperature in the dark for 15min. Immediately before analysis by
ﬂow cytometry, 400L binding buffer was added to each sample.
Two-color analysis of apoptosis was done using a BD FACSCalibur
System (BD Biosciences). Fluorescence compensation on the ﬂow
cytometer was adjusted to minimize overlap of the FITC and pro-
pidium iodide signals. A total of 1.2×104 cells were acquired for
eachsampleandamaximumof1×104 cellswithin thegated region
were analyzed.
Cytochrome c release
DMSO or compound JCC76 treated LTEDaro cells were col-
lected and triturated with 100L of chilled hypotonic lysis
solution [220mmol/Lmannitol, 68mmol/L sucrose, 50mmol/L KCl,
5mmol/L EDTA, 2mmol/L MgCl2 and 1mmol/L DTT in 50mmol/L
PIPES-KOH (pH 7.4)] for 45min. The solution was centrifuged
at 600× g for 10min to collect the supernatant. The super-
natant was further centrifuged at 14,000 rpm for 30min, and
equal amounts of proteins (50g) from the supernatant were
resolved in 15% SDS-polyacrylamide gel. Proteins were transferred
to nitrocellulose membranes and analyzed by immunoblotting
with anti-cytochrome c antibodies [32].
Animal experiment
Five- to six-week-old female BALB/c nu/nu, athymic, ovariec-
tomized mice were purchased from Charles River Laboratories,
Inc. (Wilmington, MA). LTEDaro cells were routinely maintained
in MEM, supplemented with 10% charcoal-stripped fetal bovine
serum (FBS), 2mmol/L l-Glutamine, 1mmol/L sodium pyruvate,
100U/mL penicillin–streptomycin and 200mg/L G418 (Invitrogen,
Carlsbad, CA). Subconﬂuent cells were harvested from monolayer
culture and resuspended in an equal volume of Matrigel (BD Bio-
sciences, San Jose, CA) to a ﬁnal concentration of 1×107/0.2mL.
At 10 weeks of age, each animal received s.c. inoculations in one
site per ﬂank with 200L of LTEDaro cell suspension. Six animals
were randomly grouped into two. Tumors were measured twice
weekly with calipers, and tumor volume was calculated by the fol-
lowing formula 4/3r21 × r2, where r1 is the smaller radius and r2
is the larger radius. Treatments began when the tumors reached a
measurable size (∼100mm3). One group (n=3) was injected s.c.
100mg/kg/48h with compound JCC76. The second group (n=3)
received the vehicle (DMSO) and served as control group. Body
weights were monitored weekly as an indicator of the animals’
overall health.After18daysof treatment, themicewereeuthanized
and the tumors were removed, weighed, and sent for hematoxilin
and eosin (H & E) histological staining through the Cleveland Clinic
Core Facility. Tumor specimens were also stained using cleaved-
caspase-3 antibody (Cell Signaling Technology, Danvers, MA) for
apoptosis and Ki-67 antibody (Dakocytomation, Carpinteria, CA)
staining for cell proliferation. Data are expressed as mean± SEM
(n≥5).
Statistical analysis
Statistical and graphical information was determined using
GraphPad Prism software (GraphPad Software Incorporated) and
Microsoft Excel (Microsoft Corporation). Determination of IC50
values was performed using nonlinear regression analysis. Statis-
tically signiﬁcant differences were calculated with the two-tailed
unpaired Student’s t-test and P values reported at 95% conﬁdence
intervals.
Results
Characterization of LTEDaro cells
MCF-7aro cells express high level of aromatase which converts
androgen to estrogen in the cells. Estrogen then stimulates the cell
proliferation by ER pathways. This stimulation was inhibited by
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AIs (Fig. 2A). LTEDaro was developed from MCF-7aro by hormone
deprivation over a year, which mimicked the estrogen deprivation
condition for the ER positive breast cancer patients in clinic. The
cells were no longer sensitive to androgen and estrogen after this
process. Subsequently, they were not responding to AI treatment
anymore in thecell proliferationassay (Fig. 2B). Several laboratories
developed similar models to study endocrine resistance mecha-
nisms [6–8,33]. Itwas demonstrated that IGFR (Insulin-likeGrowth
Factor) and/or Her2 growth factor pathways were up-regulated in
these cells, and that downstream pathways of these growth fac-
tors were activated [6,33]. Corresponding signaling transduction
inhibitors restored sensitivity to AIs in these cells [9–11,34]. In
our LTEDaro model, we found similar, but slightly different phe-
nomenon from other studies (Fig. 2C). Her2 protein expressionwas
signiﬁcantly increased, but IGFR remained the same. The level of
activity of the Her2 downstream kinase, pERK, was signiﬁcantly
increased where pAKT activity remained the same. These results
suggest that theMAPK (mitogen activated protein kinase) pathway
was up regulated in our LTEDaro cells. In addition, the expression
of the antiapoptotic protein BCL-2 was increased in LTEDaro cells,
compared with that in MCF-7aro cells. The level of pBAD expres-
sion was increased where BCL-XL was only slightly increased. This
could prevent BAD and BCL-2 family dimerization and protect the
cells from apoptosis. These results suggest that the Her2 overex-
pression and anti-apoptotic protein up-regulation are responsible
for AI resistance in LTEDaro cells. Her2 inhibitor AG825 exhib-
ited clar toxic effect to LTEDaro cells at 10M (data not shown),
whichmatches with several reports in which Her2mono-antibody
Trastuzumab, PI3K inhibitorwortmannin could inhibit LTEDaro cell
growth [10,11].
Compound JCC76 signiﬁcantly inhibited LTEDaro cell growth
COX-2 inhibitor nimesulide inhibited cancer cell growth at
200–500M concentrations and has been reported in many stud-
ies [35–38]. This agent did not showany selectivity of the inhibition
among these cancer cells. It is more like a general cytotoxic agent
to the cancer cells. Interestingly, its analogs selectively inhibited
Her2 over-expressing breast cancer cell growth [26,39]. Since Her2
is unregulated in AI resistant breast cancer cells, it is very likely that
nimesulide analogs are able to overcome AI resistance. Compound
JCC76 (Fig. 1) is a lead compound from the nimesulide derivative
pool [25,39]. It selectively inhibited the proliferation of SK-BR-3
and BT474 breast cancer cells which all express Her2 protein in
previous studies [39]. We hypothesize that the compound might
be able to inhibit LTEDaro breast cancer cell growth since the cells
depend on the elevated Her2 signal for proliferation. To test our
hypothesis, experiments were performed to determine whether
compound JCC76 could do so. The results exhibited that compound
JCC76 signiﬁcantly inhibited LTEDaro cell growth with an IC50 of
2.75±0.31M (Fig. 3A). Further study reveals that the inhibition
was time-dependent (Fig. 3B). However, it is unclear whether this
is just a general cytotoxic effect or JCC76 selectively interfere with
the Her2 pathway to achieve this biological effect. To answer this
question, we examined whether the compound inhibits the prolif-
eration of other breast cancer cells. The Her2 over-expressing cell
lines LTEDaro, SKBR-3, and the Her2 negative cells (MDA-MB-231,
HCC38 and BT20) were used to study the selectivity of compound
JCC76. The results revealed that JCC76 selectively inhibited LTEDaro
and SKBR-3 breast cancer cell growth (Fig. 3C). More speciﬁ-
cally, it inhibited SKBR-3 cell growth with IC50 of 1.80±0.31M,
MDA-MB-231 cell growthwith IC50 of 22.35±2.16M, HCC38 cell
growth with IC50 of 20.03±1.23M and BT20 cell growth with
IC50 of 29.77±4.13M. These results showed the selectivity of the
compound on Her2 positive breast cancer cells verses Her2 neg-
ative breast cancer cells, which matches with our previous study
Table 1
Altered cell cycle distribution of LTEDaro cells in response to JCC76 treatment.
LTEDaro cells were treated with the compound for 48h. Cells were processed for
FACS using propidium iodide staining as described in Section 2. Percent distribution
of cells in each cell cycle phase was displayed.
JCC76 Sub-G1% G1% S% G2/M% Dead cells
DMSO 4.82 64.71 21.76 7.18 1.53
1.0 (M) 6.42 67.66 18.65 5.32 1.95
5.0 (M) 20.61 38.43 22.32 9.07 9.57
10.0 (M) 22.94 18.12 24.1 14.2 20.64
[26].
Compound JCC76 did not cause cell arrest, but signiﬁcantly
induced LTEDaro cell apoptosis
JCC76 may inhibit LTEDaro cell growth by causing cell cycle
arrest, producing necrosis, or inducing apoptosis. Several experi-
ments were performed to assess the possible mechanisms of cell
growth inhibition of compound JCC76. Firstly, in the cell cycle
study, a signiﬁcant amount of cellswere halted in the Sub-G1phase
(Table 1), which indicated cell apoptosis. The G1/S ratio did not
change signiﬁcantly at 1M. Only after 5 and 10M treatment,
G1/S was dramatically changed, but mainly due to cell death (Data
not shown). This suggests that the compound did not cause cell
cycle arrest. Secondly, LTEDaro cells treated with JCC76 shrank,
rounded, and detached from the dish, as shown in Fig. 4A by phase-
contrastmicroscopy.Morphological evidence of apoptosiswas also
provided by nuclear fragmentation detected by staining cells with
theDNA-bindingﬂuorescent chromatin dyeHoechst 33342. A large
portion of the cells treated with JCC76 at 5 and 10M for 48h had
apoptotic bodies and/or irregularly punctate nuclei, characteris-
tic of cells undergoing programmed cell death (Fig. 4A). Thirdly,
apoptosis was assessed by using a Cell Death Detection ELISA
(Roche Diagnostics, Mannheim, Germany). This test is based on
the quantitative determination of cytoplasmic histone-associated
DNA fragments in the form of mononucleosomes and oligonucle-
osomes after induced apoptotic death (Fig. 4B). Signiﬁcant DNA
fragmentation was shown after the treatment of JCC76 at 5 and
10M for 48h. Fourthly, apoptosis was detected by the analysis
of phosphatidylserine externalization using Annexin V, as shown
in Fig. 4C. After normalization to the control cells treated with
DMSO, JCC76 at 5 and 10M induced 54% and 78% apoptotic death
in LTEDaro cells after a 48h treatment, respectively. Finally, apo-
ptosis was characterized by western blot analysis of the 85-kDa
apoptosis-speciﬁc cleavage fragment of PARP (Fig. 4D). After 24h,
the sample treated with 10M JCC76 showed a clear 85-kDa frag-
ment; after 48h, both 5 and10MJCC76 treatments resulted in the
cleavage of PARP. All of these results demonstrated that the com-
pound induced apoptosis in LTEDaro cells, suggesting that it could
overcome AI resistance in breast cancer cells through the induction
of cell apoptosis.
Compound JCC76 decreased the levels of pAKt, BCL-2 and
pBAD112 in LTEDaro cells.
To further explore themechanisms of apoptosis in LTEDaro cells
inducedby JCC76,Her2downstreamPI3K/AKtandMAPKpathways,
apoptosis related BCL-2 family proteins which were up regulated
in LTEDaro cells, were examined after the treatment of the com-
pound. Itwas found that protein levels of pAKt, pBAD112 andBCL-2
decreased, as shown in Fig. 5. The results suggest that JCC76 was
able to suppress the growth factor-mediated signals which are up-
regulated after long-term estrogen deprivation of MCF-7aro cells.
In addition, cytochrome c release was observed after the treat-
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Fig. 6. In vivo effect of JCC76 on LTEDaro breast cancer tumor growth. Five- to six-week-old female BALB/c nu/nu, athymic, ovariectomized mice were given injections of
LTEDaro cells in Matrigel (BD Biosciences, San Jose, CA). After tumor reach measurable size, the animals were treated with either JCC76 (in DMSO) s.c. or DMSO control every
other day for 18 days. Mice were then euthanized and A: tumor weights (n=3 for each group); B: tumor size (n=3 for each group); C: mice weights (n=3 for each group); D:
cleaved-caspase-3 antibody staining for apoptosis; and E:Ki-67 antibody staining for cell proliferation were evaluated. Five identical sizes of areas with the staining slides
were randomly picked for counting, and the counting numbers were plotted. Data represent mean in each group (n≥5± standard error of the mean in Figure D and E). *
indicates statistical signiﬁcance from the control group (P≤0.05);*** indicates statistical signiﬁcance from control group (P≤0.005).
ment of JCC76, which indicated that apoptosis was mediated by
the mitochondria.
Induction of apoptosis in vivo
To examine the overcomingAI resistance effects of JCC76 in vivo,
we investigated the ability of the compound to induce LTEDaro-
derived tumor apoptosis in female, ovariectomized nude mice.
The mice bearing LTEDaro xenograft were treated for only 18
days, because the tumor size in the treatment group was signif-
icant decreased, which may limit the tumor tissue quantity for
the histological examination if the experiment was continued.
The results of the in vivo experiment showed that the treatment
of JCC76 slightly decreased LTEDaro tumor weight and signiﬁ-
cantly decreased tumor size compared to control mice (Fig. 6A
and B). The compound showed low toxicity to the mice since
the mouse weights of the treatment group were not decreased
(Fig. 6C). Histological examination of LTEDaro tumors revealed that
cell proliferationmarker Ki-67was not changed in the JCC76 group
compared to the control, whereas the level of apoptosis marker
cleaved caspase-3 in the treated tumorswas increased signiﬁcantly
(Fig. 6D and E). The data illustrated the ability of JCC76 to induce
apoptosis of AI-insensitive breast cancer cells in vivo.
Discussion
AIs have been proven to be more effective than tamoxifen
for hormone dependent breast cancer [2]. However, resistance to
AIs eventually develops after long-term usage, which has been
reported in preclinical animal models by several laboratories as
well as in clinical studies [5,7,9,33,34]. Therefore, it is important
to ﬁnd additional strategies to control tumor growth after patients
fail AI treatment. Due to the unique character of LTEDaro cell, it
is generally used as a model to search new agents to overcome AI
resistance. Her2 and its downstream molecule pERK, and the anti-
apoptoticproteinBCL-2wereall elevated in this endocrine resistant
cell line,which could promote cell survival. These results also agree
with the reports that Her-2 transfectedMCF-7 cells showed higher
BCL-2 protein compared with parental cells [40–42]. Furthermore,
pBAD protein levels were also increased which could prevent BAD
and BCL-2 family protein dimerization and protect the cells from
apoptosis. Such ﬁndings indicate that protecting cells from apo-
ptosis could be one of the mechanisms for resistance to AIs.
To search for new agents that can overcome AI resistance has
been a new task in ER positive breast cancer research ﬁeld. Many
small molecules that interfere with Her2 downstream had been
tested. Some of the compounds worked well in the in vitro model,
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but show marginal effects in the clinic [34]. There is no clear
explanation for this phenomenon yet. We focus our research on
screening other agents to overcome AI resistance. The effects of
a novel COX-2 inhibit nimesulide analog JCC76 was examined
in the AI resistance model LTEDaro cells. The rationale for the
study is based on the observation that nimesulide analogs selec-
tively inhibited Her2 over-expressing breast cancer cell growth,
and Her2 protein is signiﬁcantly unregulated in AI resistant breast
cancer. Our results demonstrated that JCC76 dramatically inhib-
ited LTEDaro cell growthwith a sub-micromole IC50. Several assays
were performed to examine if JCC76 can cause cell cycle arrest
or apoptosis in LTEDaro cells. Results from these experiments
revealed that the agent did not cause cell cycle arrest, and it
mainly inhibited cell growth via induction of LTEDaro cell apo-
ptosis. Furthermore, the results proved that JCC76 was able to
decrease pAKt, pBAD112 and BCL-2 protein levels. These three pro-
teins are involved in the regulation of cell apoptosis. Our ﬁndings
suggest that JCC76 inhibited LTEDaro cell growth via promoting
cell apoptosis, probably through the mitochondria pathway since
cytochrome-c released from mitochondria was increased after the
compound treatment. In addition, JCC76 was found to selectively
inhibit Her2 over-expressing breast cancer cell growth among a
panel of breast cancer cell lines. This agrees with the results show-
ing that compound JCC76 interfered somemolecules related to the
Her2 pathway. In addition, our in vivo studies illustrated that treat-
ment of JCC76 suppressed the growth of LTEDaro tumors in mice
without affecting theweight of the animals. This result showed that
the compound was active in vivo and low toxic to the animals. Fur-
ther, the suppression of growth was due to induction of apoptosis
as measured by cleaved caspase-3 antibody staining. This result is
in agreement with the in vitro results.
In conclusion, we investigated the mechanisms of JCC76 for
selectively inhibiting LTEDarobreast cancer cell growth. The results
demonstrated that the compound was able to overcome AI resis-
tance via induction of cell apoptosis. Our results have revealed
several proteins that play roles in JCC76-mediated apoptosis. These
anticancer properties of JCC76 make it a potential new therapeu-
tic agent for overcoming AI-resistance. Further optimization of this
compound to generate more potent derivatives is currently under-
way.
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